: One of the year's biggest winners, surging 438% . The biotech firm saw its valuation jump from roughly $200 million to over $1.4 billion following a key collaboration with a major pharmaceutical player.
: Returned 373% after receiving FDA approval for its hepatitis B vaccine. top stocks to buy 2017
: Gained 387% due to positive developments in its painkiller and immuno-oncology portfolio. : One of the year's biggest winners, surging 438%